Compare American Homes 4 Rent Class A (AMH) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Homes 4 Rent Class A vs Novo Nordisk A/S — how do they compare? American Homes 4 Rent Class A trades at $33.27 (market cap $11.97B), while Novo Nordisk A/S trades at $49.17 (market cap $216.71B). The key difference: Novo Nordisk A/S is far larger — about 18.1× American Homes 4 Rent Class A's market cap, and American Homes 4 Rent Class A pays the higher dividend (3.97%). Which is the better fit depends on your goals.
| AMH | NVO | |
|---|---|---|
Market Cap | $11.97B | $216.71B |
Sector | Real Estate | Health |
52-Week High | $36.74 | $71.70 |
52-Week Low | $27.38 | $35.29 |
Enterprise Value | $17.05B | $235.67B |
Dividend Yield | 3.97% | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMH (American Homes 4 Rent) trades at $33.27, up 1.0% with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The company maintains robust fundamentals with 24.48% net income margin and $1.85B revenue in 2025, supported by 95% occupancy rates in the single-family rental market. Recent dividend declaration of $0.33 per share and positive analyst sentiment with 58% buy ratings reinforce strength.
Outlook remains positive given consistent operational performance and strategic focus on Sunbelt and Midwest markets. Key risks include high debt levels at $5.01B and sensitivity to interest rate changes. With consensus price target of $35.68 offering 7.2% upside, the stock presents a compelling opportunity for income and growth investors despite macroeconomic headwinds.
Novo Nordisk (NVO) trades at $49.48, up 1.23% today, with a bullish technical signal from moving averages and strong fundamentals including a 37.2% net income margin and 71.4% ROE. Recent earnings beats in Q3 2025-Q1 2026 highlight operational strength, while cash flow remains positive at $10.81B in 2025. The stock benefits from GLP-1 drug leadership, with oral Wegovy driving market expansion amid competitive pressures.
Outlook is positive with analyst consensus at 57.9% buy ratings, but risks include prescription slowdown concerns and rising debt-to-asset ratio to 22.54 in 2025. Investment appeal lies in robust profitability and growth in obesity/diabetes treatments, though investors should monitor competition and execution on guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Homes 4 Rent Class A
American Homes 4 Rent is a real estate investment trust primarily focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's largest geographical markets include Dallas, Texas
Read more on AMH →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
